Bausch Health Companies Inc. Long-Term Debt, Maturity, Year Five
Bausch Health Companies Inc. (BHC) had Long-Term Debt, Maturity, Year Five of $3.90 billion as of 2026-06-30, per its 10-Q filed 2026-07-30.
Financial Statements › Notes › Commitment and Contingencies › Long-Term Debt, Fiscal Year Maturity › Long-Term Debt, Maturity, Year Four and Five
us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive · last filed 2026-07-30
- 2026-06-30: Long-Term Debt, Maturity, Year Five $3.90B.
- 2026-03-31: Long-Term Debt, Maturity, Year Five $3.91B.
- 2025-12-31: Long-Term Debt, Maturity, Year Five $4.12B.
- 2025-09-30: Long-Term Debt, Maturity, Year Five $4.02B.
| Period end | Long-Term Debt, Maturity, Year Five |
|---|---|
| 2026-06-30 | $3.90B 10-Q · filed 2026-07-30 |
| 2026-03-31 | $3.91B 10-Q · filed 2026-04-30 |
| 2025-12-31 | $4.12B 10-K · filed 2026-02-19 |
| 2025-09-30 | $4.02B 10-Q · filed 2025-10-30 |
| 2025-06-30 | $4.02B 10-Q · filed 2025-07-31 |
| 2024-12-31 | $1.61B 10-K · filed 2025-02-20 |
| 2024-09-30 | $1.61B 10-Q · filed 2024-10-31 |
| 2024-06-30 | $1.61B 10-Q · filed 2024-08-01 |
| 2024-03-31 | $1.61B 10-Q · filed 2024-05-02 |
| 2023-12-31 | $7.22B 10-K · filed 2024-02-22 |
| 2023-09-30 | $7.22B 10-Q · filed 2023-11-02 |
| 2023-06-30 | $4.99B 10-Q · filed 2023-08-03 |
| 2023-03-31 | $4.99B 10-Q · filed 2023-05-04 |
| 2022-12-31 | $6.94B 10-K · filed 2023-02-23 |
| 2022-09-30 | $6.93B 10-Q · filed 2022-11-03 |
| 2022-06-30 | $8.00B 10-Q · filed 2022-08-09 |
| 2022-03-31 | $3.25B 10-Q · filed 2022-05-10 |
| 2021-12-31 | $1.50B 8-K · filed 2022-05-11 |
| 2021-09-30 | $1.50B 10-Q · filed 2021-11-02 |
| 2021-06-30 | $1.50B 10-Q · filed 2021-08-03 |
| 2021-03-31 | $1.50B 10-Q · filed 2021-05-04 |
| 2020-12-31 | $10.63B 8-K · filed 2021-05-04 |
| 2020-09-30 | $10.63B 10-Q · filed 2020-11-03 |
| 2020-06-30 | $10.63B 10-Q · filed 2020-08-06 |
| 2020-03-31 | $2.30B 10-Q · filed 2020-05-07 |
| 2019-12-31 | $2.30B 10-K · filed 2020-02-19 |
| 2019-09-30 | $3.79B 10-Q · filed 2019-11-04 |
| 2019-06-30 | $4.11B 10-Q · filed 2019-08-06 |
| 2019-03-31 | $5.44B 10-Q · filed 2019-05-06 |
| 2018-12-31 | $6.35B 10-K · filed 2019-02-20 |
| 2018-09-30 | $1.48B 10-Q · filed 2018-11-06 |
| 2018-06-30 | $1.48B 10-Q · filed 2018-08-07 |
| 2018-03-31 | $5.12B 10-Q · filed 2018-05-08 |
| 2017-12-31 | $5.12B 8-K · filed 2018-08-10 |
| 2017-09-30 | $3.17B 10-Q · filed 2017-11-07 |
| 2017-06-30 | $3.52B 10-Q · filed 2017-08-08 |
| 2017-03-31 | $3.52B 10-Q · filed 2017-05-09 |
| 2016-12-31 | $3.21B 10-K · filed 2017-03-01 |
| 2015-12-31 | $7.83B 10-K · filed 2016-04-29 |
| 2014-12-31 | $1.96B 10-K · filed 2015-02-25 |
| 2013-12-31 | $3.50B 10-K · filed 2014-02-28 |
| 2012-12-31 | $523.00M 10-K · filed 2013-02-28 |
| 2011-12-31 | $2.14B 10-K · filed 2012-02-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| OCULAR THERAPEUTIX, INC (OCUL) | United States | $2.159B | -7.15 |
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| Aurinia Pharmaceuticals Inc. (AUPH) | $2.207B | 7.18 | |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 |